E. Marshall

发表

Phase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrence.

P. Lorigan, Cheng Han, M. Middleton, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MRI in the detection of hepatic metastases from high-risk uveal melanoma: a prospective study in 188 patients

P. Ghaneh, B. Damato, S. Coupland, 2012, British Journal of Ophthalmology.

Uveal Melanoma UK National Guidelines.

B. Stedman, P. Szlosarek, P. Nathan, 2015, European journal of cancer.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

D. Schadendorf, A. Testori, S. Leyvraz, 2014 .

Explorer Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

A. Clamp, J. Hasan, S. Mullamitha, 2017 .

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

G. Jayson, A. Clamp, J. Hasan, 2005, British Journal of Cancer.

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

P. Clark, G. Ross, E. Marshall, 2001, Oncology.

RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases – results and lessons learnt

S. Love, C. Roberts, M. Middleton, 2016, British Journal of Cancer.

CAN PERIODIC SURVEILLANCE FOR METASTASES IMPROVE CLINICAL OUTCOME IN UVEAL MELANOMA? MOVING TOWARDS INTERNATIONAL GUIDELINES

J. Sacco, E. Marshall, 2013 .

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

D. Schadendorf, A. Testori, S. Leyvraz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A multi-centre phase IIB randomized controlled study of BLP25 liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis: B1-01

P. Ellis, A. Price, Y. Cormier, 2007 .

Phase II trial Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF Melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

D. Schadendorf, S. Love, C. Mauch, 2018 .

Phase II trial of edatrexate in relapsed or refractory germ cell tumors: A Southwest Oncology Group study (SWOG 9124)

S. Balcerzak, W. Samlowski, E. Crawford, 1998, Investigational New Drugs.

Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.

D. Schadendorf, P. Dziewulski, A. Eggermont, 2020, European journal of cancer.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy induced febrile neutropenia: management and prevention.

H. Innes, E. Marshall, 2008, Clinical medicine.

Validation of a Prognostic Staging for Metastatic Uveal Melanoma: A Collaborative Study of the European Ophthalmic Oncology Group.

L. Desjardins, S. Leyvraz, S. Piperno-Neumann, 2016, American journal of ophthalmology.

A randomized phase-II study of BB-10010 (macrophage inflammatory protein- 1alpha) in patients with advanced breast cancer receiving 5-fluorouracil, adriamycin, and cyclophosphamide chemotherapy.

A. Howell, H. Earl, D. Miles, 1998, Blood.

The Liverpool uveal melanoma liver metastases pathway: Outcome following liver resection

P. Ghaneh, B. Damato, S. Fenwick, 2014, Journal of surgical oncology.

Management of febrile neutropenia in the United Kingdom: time for a national trial?

L. Billingham, N. Steven, C. Gaunt, 2005, British Journal of Cancer.

Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.

A. Howell, T. Dexter, L. Czaplewski, 1998, European journal of cancer.

Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide.

B. Lord, E. Marshall, L. Woolford, 1997, British Journal of Cancer.

Ambulatory emergency oncology: A key tenet of future emergency oncology care

D. Lasserson, T. Cooksley, T. Rice, 2020, International journal of clinical practice.

Neutropenic sepsis: a potentially life-threatening complication of chemotherapy.

A. Ford, E. Marshall, 2014, Clinical medicine.

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

H. Innes, A. Hall, E. Marshall, 2008, Supportive Care in Cancer.

Outpatient therapy for febrile neutropenia

H. Innes, E. Marshall, 2007, Current opinion in oncology.

Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study

P. Clark, D. Smith, H. Innes, 2003, British Journal of Cancer.

The impact of a new acute oncology service in acute hospitals: experience from the Clatterbridge Cancer Centre and Merseyside and Cheshire Cancer Network.

H. Wong, E. Marshall, H. Neville-Webbe, 2013, Clinical medicine.

Ten-year survival in advanced malignant melanoma following treatment with interferon and vindesine.

J. Green, M. Iqbal, E. Marshall, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial

P. Ellis, A. Price, Y. Cormier, 2011, Journal of Cancer Research and Clinical Oncology.

A Randomized Phase-II Study of BB-10010 (Macrophage Inflammatory Protein- 1) in Patients With Advanced Breast Cancer Receiving 5-Fluorouracil, Adriamycin, and Cyclophosphamide Chemotherapy

A. Howell, H. Earl, D. Miles, 1998 .

Feedback inhibitors in normal and tumor tissues.

B. Lord, E. Marshall, 1996, International review of cytology.

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer - EORTC 08062.

C. Fink, A. Dingemans, J. V. van Meerbeeck, 2011, European journal of cancer.

Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.

E. Crawford, M. Eisenberger, M. Hussain, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

D. Schadendorf, C. Mauch, S. Love, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

M. Gore, P. Nathan, P. Lorigan, 2014, The Lancet. Oncology.

Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.

P. Huppert, S. Patel, S. Leyvraz, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma.

J. Larkin, P. Nathan, P. Lorigan, 2016 .

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.

P. Ellis, P. Ellis, A. Price, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma

B. Redman, H. Zarour, S. O’Day, 2009, Cancer.

Ambulatory management in low risk neutropenic sepsis - A plea for integrated acute cancer care.

E. Marshall, 2019, Acute medicine.

Extensive necrosis of visceral melanoma metastases after immunotherapy

G. Poston, N. de Liguori Carino, E. Marshall, 2007, World journal of surgical oncology.

Reconciling the principle of patient autonomy with the practice of informed consent: decision‐making about prognostication in uveal melanoma

B. Damato, P. Salmon, S. Cook, 2011, Health expectations : an international journal of public participation in health care and health policy.

A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma

C. Eswar, M. Butt, P. A. O'neill, 2006, Melanoma research.

BB-10010/MIP-1 alpha in vivo maintains haemopoietic recovery following repeated cycles of sublethal irradiation.

B. Lord, M. Hunter, E. Marshall, 1996, British Journal of Cancer.

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

G. Rosner, M. Ratain, David Palchak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents.

P. Selby, M. Krzyzanowska, F. Collinson, 2016, The oncologist.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

C. Boshoff, A. Hackshaw, S. Upadhyay, 2012, The Lancet. Oncology.

Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer.

M Buyse, M. Buyse, R. Schilsky, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.

J. Larkin, P. Nathan, P. Lorigan, 2013 .

Psychological aspects of cytogenetic testing of uveal melanoma: preliminary findings and directions for future research

B. Damato, P. Salmon, S. Cook, 2009, Eye.

Randomized phase III trial of intravenous (IV) versus hepatic intra-arterial (HIA) fotemustine in patients with liver metastases from uveal melanoma: Final results of the EORTC 18021 study.

D. Schadendorf, A. Testori, S. Leyvraz, 2012 .

Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.

M. Gore, P. Nathan, P. Lorigan, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Multifocal calcifying fibrous tumor at six sites in one patient: a case report

E. Marshall, F. Azam, M. Latif, 2014, World Journal of Surgical Oncology.

Using QR codes to enable quick access to information in acute cancer care.

J. Sacco, A. Olsson-Brown, E. Marshall, 2017, British journal of nursing.

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial.

D. Schadendorf, A. Testori, S. Leyvraz, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of tamoxifen and goserelin in recurrent epithelial ovarian cancer

A. Clamp, J. Hasan, S. Mullamitha, 2005, British Journal of Cancer.

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

C. Boshoff, A. Hackshaw, S. Upadhyay, 2012, The Lancet. Oncology.

Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC).

Y. Cormier, C. Butts, D. Soulières, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

M. Gore, A. Dalgleish, P. Nathan, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized phase II study (EORTC 08062) of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients (pts) with extensive disease small cell lung cancer (ED SCLC).

A. Dingemans, J. Jassem, P. Lorigan, 2010 .